United States: Plaintiff Attorney Advertising: Protected Or Prosecutable?

The barrage of plaintiff-attorney advertisements soliciting plaintiffs for drug and device litigation may spawn calls by executives, board members, and other company decision-makers to find out what can be done to stop them. Although certain categories of advertising are constitutionally protected as "free speech," developing precedent shows that attorney advertising may be susceptible to legal challenges under the Lanham Act. These claims have not been tested in court, but they present a legitimate possibility for manufacturers to mount an offensive attack against certain advertisements. This article provides an overview of the constitutional protections afforded attorney advertising in the United States, followed by an overview of new precedent under the Lanham Act and how it may be applied to combat certain advertising.


Attorney advertising in the United States is well established as constitutionally protected commercial speech. In March 1975—when many state bar associations prohibited any form of attorney advertising—two lawyers in Arizona defied their state bar association's regulation prohibiting any form of attorney advertising and placed a newspaper ad that read: "DO YOU NEED A LAWYER? LEGAL SERVICES AT VERY REASONABLE FEES."1 When the Arizona State Bar suspended the lawyers for placing the ad, they challenged the disciplinary rule, paving the way for lawyer advertising to become protected free speech under the First Amendment.

The case, Bates v. State Bar of Arizona, reached the Supreme Court, which found outright bans on advertising like that imposed by the Arizona state bar to be unconstitutional.2 The Court specifically rejected the premise that advertising eroded "true professionalism" in the legal field, and determined instead that it was protected commercial speech.3 Bates was the end of absolute bans on attorney advertising.

It didn't take long for attorney advertising to develop into a vehicle for mass torts, starting in the 1980s with an attorney's advertisement in 36 Ohio newspapers soliciting women who used the Dalkon Shield Intrauterine Device.4 This advertisement contained a drawing of the device, asked the question "DID YOU USE THIS IUD?" and claimed that the device was "alleged to have caused serious pelvic infections resulting in hospitalizations, tubal damage, infertility, and hysterectomies."5 The ad offered legal representation, noting that "[i]f there is no recovery, no legal fees are owed by our clients."6 The Ohio Office of Disciplinary Counsel found such advertising was not sufficiently "dignified" or limited in scope to permissible information under its rules prohibiting illustrations and self-recommendation.7 It also found the ad violated a rule requiring that contingency-fee rates should disclose whether the percentages were computed before or after costs and expenses.8 The Supreme Court held that—except with regard to the misleading contingency fee statement—the advertisement's statements and illustration regarding the IUD were not false or misleading and were entitled to First Amendment protection.9


The American Bar Association's Model Rules of Professional Conduct ("Model Rules") serve as a standard for state bar associations, and each of the 50 states and the District of Columbia have adopted some variation of the Model Rules.10 The initial ethics rules, published in 1908, sought to compile a collection of norms for all attorney conduct.11 Solicitation by advertisement was deemed "unprofessional" and all forms of "self-laudation" were "intolerable," "defy[ing] the traditions and lower[ing] the tone of our high calling."12 Indeed, the best advertisement was "the establishment of a well-merited reputation for professional capacity and fidelity to trust."13

The ABA Model Rules published in 1983—after Bates—permitted attorney advertising through various publication modes, including television.14 The 1983 Model Rules also put specific limits on lawyers' direct solicitation of prospective clients and on lawyers' statements about certification fields of practice,15 but several Supreme Court rulings striking down state rules similar to the Model Rules spurred amendments.16 Further amendments resulted in the key prohibition on attorney advertising being limited to a showing that it is false or misleading speech.17 Under the Model Rules, an advertisement is "false or misleading if it contains a material misrepresentation of fact or law, or omits a fact necessary to make the statement considered as a whole not materially misleading."18 The result from the dilution of restrictions on advertising in the Model Rules following Bates is that most attorney advertising soliciting drug or device plaintiffs is permitted by state bar associations.


Given the unlikelihood that state bar associations will pursue enforcement actions against attorney advertising, challenges by manufacturers must instead be made under common-law theories such as defamation and business torts or statutory claims under the Lanham Act. These claims focus not on statements about the lawyer or the lawyer's services, but on the content of the advertising that relates to a company's products and the impact of the advertisement on those products.

The most straightforward example of advertising that is "false or misleading" and susceptible to challenge is an ad that is obviously false. For example, an ad that claims a drug or medical device has been recalled by the FDA when in fact it has not is false and subject to immediate challenge. Such ads are usually addressed through cease-and-desist letters without the need for litigation.

Other examples of obvious falsity include misstatements about the product itself. For example, in 2011, Zimmer, Inc. sued Pulaski & Middleman, LLC—infamous for its "1-800-BADDRUG" ads—for "making false, misleading and defamatory statements about Zimmer and [its] NexGen® Knee System" in television advertisements.19 Zimmer alleged that the Pulaski Firm's ad was false or misleading by saying: "Reports show the ZIMMER NEXGEN KNEE IMPLANT MAY HAVE A FAILURE RATE OF 9%."20 Zimmer sued for defamation, tortious interference with business relationships, false advertising under the Lanham Act, product disparagement, and several trademark theories.21 The parties reached a confidential settlement, summarized by Zimmer in a public statement that the law firms "retracted the misleading claims in their advertisements" and that the firms would run corrective statements on their respective websites for six months. Zimmer's statement also indicated that the law firms either paid a monetary settlement, issued a retraction, or did both.22 Pulaski & Middleman's statement on its website admitted that it had "determined that the sources we previously relied upon to make claims about the Zimmer NexGen Knee System do not support the statements or implication" in the ads.23

While the Zimmer example is informative when an attorney advertisement obviously misstates factual information about a product, the more difficult question arises when an advertisement is not per se false, but is arguably misleading. Although claims for defamation and business torts remain options, recent precedent under the Lanham Act suggests that drug and medical-device manufacturers may have a better avenue to combat false or misleading advertising.


The Lanham Act provides a federal cause of action akin to unfair competition claims. The Act's provision regarding false advertising states:

(1) any person who, on or in connection with any goods or services . . . uses in commerce any word, term, name, symbol, or device, or any combination thereof, or any . . . false or misleading representation of fact which—

(B) in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographic origin of . . . another person's goods services or commercial activities,

shall be liable in a civil action by any person who believes that he or she is likely to be damaged by such act."24

Traditionally, a false-advertising claim under the Lanham Act arises when "one competito[r] directly injur[es] another by making false statements about his own goods [or the competitor's goods] thus inducing customers to switch."25 This underscores that any Lanham Act falseadvertising claim must be framed around economics—the manufacturer is losing business on the drug or device because of the defendant law firm's false advertising about that drug or device.


The initial hurdle under the Lanham Act is standing to sue. Federal courts are prohibited from hearing cases in which the plaintiff has not "suffered or been imminently threatened with a concrete and particularized 'injury in fact'" that is traceable to the defendant's action.26 In 2014 the Supreme Court, in Lexmark International, Inc. v. Static Control Components, Inc., resolved a split in the Circuit Courts of Appeal as to the proper test for standing under the Lanham Act.27

Before Lexmark, a widely used limitation on Lanham Act claims was the "direct-competitor test," which required a plaintiff be in direct competition with the defendant in order to have standing. Under this test, a pharmaceutical or device manufacturer would not have standing to sue a law firm which would not be in competition with it. Lexmark rejected this approach, concluding that "a rule categorically prohibiting all suits by noncompetitors would read too much into the Act's reference to 'unfair competition.'"28 The Court noted that when the Lanham Act was adopted, noncompetitors could sue one another under the common law tort of unfair competition. Thus, it would be "a mistake to infer that because the Lanham Act treats false advertising as a form of unfair competition, it can protect only the false advertiser's direct competitors."29

The Lexmark Court determined that where a federal statute—like the Lanham Act—creates a cause of action, the plaintiff must fall within the "zone of interests" of that statute to have standing. To be "within the zone of interests in a suit for false advertising under [the Lanham Act], a plaintiff must allege an injury to a commercial interest in reputation or sales."30 Plaintiffs must also show that their injuries are proximately caused by violation of the statute. Therefore, a manufacturer would have to show "economic or reputational injury flowing directly from the deception wrought by the defendant's advertising; and that that occurs when deception of consumers causes them to withhold trade from the plaintiff."31


Assuming that the Supreme Court's ruling in Lexmark gives pharmaceutical and medical-device manufacturers standing to pursue a Lanham Act claim, they must still prove the elements of the claim itself. Generally, a plaintiff must prove "(1) the defendant has made false or misleading statements of fact concerning his own product or another's; (2) the statement actually or tends to deceive a substantial portion of the intended audience; (3) the statement is material in that it will likely influence the deceived consumer's purchasing decisions; (4) the advertisements were introduced into interstate commerce; and (5) there is some causal link between the challenged statements and harm to the plaintiff."32

First and foremost, the focus of the claim must be that losses are suffered because a false statement influenced a consumer's purchasing decision. The fact that the advertisements result in an increase in litigation is not relevant to any claim under the Lanham Act.

An actionable statement in an advertisement "must be based upon a statement of fact, not of opinion,"33 and a plaintiff must show that the advertisement "is literally false or that it is true yet misleading or confusing."34 If a statement is literally false, the plaintiff need not show actual deception of consumers; if a statement is literally true yet misleading, the plaintiff must show that consumers' decisions to purchase were actually influenced.35 Thus, the word "bad" next to "drug" in "1-800-BAD-DRUG" would be evaluated in context to determine whether it misleads consumers. Some courts apply a presumption of damages where the deception was willful, but this presumption only applies "to cases of comparative advertising where the plaintiff's product was specifically targeted."36 Therefore, a pharmaceutical manufacturer suing a noncompetitor law firm would likely have to present "evidence of the public's reaction through consumer surveys,"37 showing "that a significant portion of the consumer population was deceived."38 These proof requirements are not easily satisfied, and consumer surveys that satisfy the Lanham Act's requirements are both expensive and time consuming..


A pharmaceutical or device manufacturer will face two hurdles in bringing this type of Lanham Act claim. First, it must prove its standing to bring the claim— that it comes within the zone of interests of the statute. Although the Supreme Court's 2014 decision in Lexmark indicates that noncompetitors may bring claims under the Act, lower courts have not yet considered the standing of noncompetitors who are in different industries altogether. Second, pharmaceutical and device manufacturers must prove all of the elements of the Lanham Act claim itself, including deception of consumers and actual reliance.


The First Amendment's protection of commercial speech allows plaintiff law firms to solicit clients through advertisements that are not false or misleading, and states' rules of professional responsibility generally only prohibit false or misleading statements by an attorney. The Lanham Act and other common-law defamation causes of action may be available, but their proof requirements are strenuous. While the Supreme Court's Lexmark decision suggests that Lanham Act claims may be available against plaintiff law firms, those claims have not been tested. And, even if lower courts apply Lexmark to permit Lanham Act claims by manufacturers against plaintiff-firms, drug and device manufacturers still face an uphill battle in combating all but patently false advertisements.


1 Bates v. State Bar of Ariz., 433 U.S. 350, 385 (1977).

2 Id. at 383.

3 Id. at 368. As "commercial speech," attorney advertising became subject to a four part test for evaluating whether regulations limiting such speech are constitutional: (1) is the speech lawful and not misleading; (2) is the government interest in regulating the speech substantial; (3) does the regulation actually advance the government interest; and (4) if the interest could be achieved by a more limited restriction on commercial speech, the limitation fails.

4 Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio, 471 U.S. 626, 630 (1985).

5 Id. at 631.

6 Id.

7 Id. at 632.

8 Id.

9 Id. at 641.

10 See Chronological List of States Adopting Model Rules, ABA, http://www.americanbar. org/groups/professional_responsibility/publications/model_rules_of_profession al_conduct/chrono_list_state_adopting_model_rules.html.

11 Colin Croft, Reconceptualizing American Legal Professionalism: A Proposal for Deliberative Moral Community, 67 N.Y.U. L. REV. 1256, 1306 (1992).

12 FINAL REPORT OF THE COMMITTEE ON CODE OF PROFESSIONAL ETHICS, Canon 27, available at http://www.americanbar.org/content/dam/aba/migrated/2011_build/professional_ responsibility/1908_canons_ethics.authcheckdam.pdf.

13 Id.

14 Model R. Prof. Conduct 7.2 (1983).

15 Model R. Prof. Conduct 7.3, 7.4 (1983).

16 See Shapero v. Ky. State Bar, 486 U.S. 466 (1988) (striking down Kentucky's rule regarding direct contact with prospective clients that was identical to the model rule); Peel v. Attorney Registration & Disciplinary Comm'n, 496 U.S. 91 (1990) (holding that states may not impose restrictions that burden a lawyer's truthful statement that he or she is a specialist, certified by an organization).

17 Model R. Prof. Conduct 7.1.

18 Id.

19 Complaint ¶¶ 53–58, Zimmer, Inc. v. Kresch/Oliver PLLC et al., No. 11CV00063, 2011 WL 767056 (N.D. Ind. Feb. 26, 2011); see also Erin Fuchs, Knee Device Maker Sues Plaintiffs Firm Over Ads, LAW360, http://www.law360.com/articles/284095/kneedevice-maker-sues-plaintiffs-firm-over-ads (Nov. 7, 2011).

20 Complaint, supra note 30, ¶ 54.

21 See id. ¶ 70–104.

22 Correcting the Record: Zimmer's Lawsuit, ZIMMERFACTS, http://zimmerfacts.com/background/index.html (last visited Jan. 29, 2016).

23 Alex Nussbaum & David Voreacos, Artificial-Knee Suits Targeting Zimmer Haunt Lawyers, BLOOMBERGBUSINESS, http://www.bloomberg.com/news/articles/2011-08-09/artificial-knee-suits-targeting- zimmer-haunt-lawyers-correct-(Aug. 9, 2011).

24 Lanham Act § 43(a), 60 Stat. 441, codified at 15 U.S.C. § 1125(a).

25 Lexmark Int'l, Inc. v. Static Control Components, Inc., 134 S. Ct. 1377, 1393 (2014) (internal quotation marks and citations omitted).

26 Id. at 1386 (citing Lujan v. Defenders of Wildlife, 504 U.S. 555, 560 (1992)).

27 134 S. Ct. 1377.

28 Id. at 1392 (citing 11 U.S.C. § 1127).

29 Id. at 1392.

30 Id. at 1390.

31 Id. at 1391.

32 Fed. Exp. Corp. v. United Parcel Serv., Inc., 765 F. Supp. 2d 1011, 1016–17 (W.D. Tenn. 2010) (quoting Am. Council of Certified Podiatric Physicians & Surgeons v. Am. Bd. of Podiatric Surgery, 185 F.3d 606, 613 (6th Cir. 1999).

33 Am. Council of Certified Podiatric Physicians & Surgeons, 185 F.3d at 614.

34 Id.

35 Id.

36 Balance Dynamics Corp. v. Schmitt Indus., Inc., 204 F.3d 683, 694 (6th Cir. 2000) (citing Porous Media Corp. v. Pall Corp., 110 F.3d 1329 (8th Cir. 1997)).

37 Id. at 616.

38 Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions